局限期前列腺癌根治性放疗联合雄激素剥夺治疗的最佳持续时间:一项荟萃分析
ADT持续时间延长对远处转移、前列腺癌特异性死亡和总生存的获益呈非线性,超过9-12个月获益减少;基于10年远处转移的最佳ADT持续时间因风险组而异。
要点
- ADT延长对远处转移、前列腺癌特异性死亡和总生存的获益呈非线性,超过9-12个月获益减少。
- 基于10年远处转移的最佳ADT持续时间:1个中危因素为0个月,≥2个中危因素为6个月,高危/极高危为12个月(原文称未定义)。
核心结论
- 对于接受根治性放疗联合ADT的局限期前列腺癌男性,延长ADT持续时间存在相对和绝对获益,有助于个体化风险估计。
研究设计与样本
- 个体患者数据荟萃分析,纳入13项随机III期临床试验,评估单纯放疗或联合ADT,中位随访11.3年(IQR 9.5-14.5),ADT持续时间0至36个月。
- 系统检索1980至2020年试验注册库、MEDLINE、Embase、Web of Science和Scopus,采用意向治疗和按治疗分析。
主要发现
- ADT持续时间延长与远处转移、前列腺癌特异性死亡和总生存的相对获益呈非线性改善,超过9-12个月后估计获益减少(取决于终点)。
- 基于10年远处转移的最佳ADT持续时间:1个中危因素患者为0个月,2个或以上中危因素患者为6个月,NCCN高危和极高危患者为12个月(原文称未定义)。
关键数值与推荐
- 基于10年远处转移的最佳ADT持续时间:1个中危因素为0个月,≥2个中危因素为6个月,NCCN高危/极高危为12个月(原文称未定义)。
- 预防10年时1例远处转移的需治疗人数(NNT)根据预后风险组计算。
临床怎么用
- 临床可根据患者风险组(1个中危因素、≥2个中危因素、高危/极高危)个体化选择ADT持续时间。
- 对于1个中危因素患者,可能无需ADT;≥2个中危因素可考虑6个月ADT;高危/极高危可考虑12个月ADT(原文称未定义)。
- 延长ADT超过9-12个月需权衡其他原因死亡风险增加(HR 1.28)。
局限性
- 原文未报告具体局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The ideal duration of androgen deprivation therapy (ADT) for treating localized prostate cancer is unknown due to variable adherence and treatment durations tested in clinical trials. OBJECTIVE: To determine the ideal duration of ADT for patients with prostate cancer treated with radiotherapy. DATA SOURCES: This individual patient data meta-analysis of 13 randomized phase 3 clinical trials evaluated the use of radiotherapy alone or with ADT. It included patients with a median follow-up of 11.3 (IQR, 9.5-14.5) years and ADT duration of 0 to 36 months. Most patients (7392 [72%]) included had National Comprehensive Cancer Network high-risk or very high-risk disease. STUDY SELECTION: For this meta-analysis, a systematic literature search from 1980 to 2020 was performed in trial registries (Cochrane Central Register of Controlled Trials and ClinicalTrials.gov), MEDLINE (1966-2020), Embase (1982-2020), Web of Science, and Scopus to identify trials. DATA EXTRACTION AND SYNTHESIS: Intention-to-treat and as-treated analyses were performed. The number needed to treat to prevent 1 distant metastasis at 10 years was calculated based on prognostic risk group. The analyses were conducted from January 5 to August 15, 2023. MAIN OUTCOMES AND MEASURES: The primary end point for this study was overall survival, defined as time to death or last follow-up from randomization. Secondary end points included biochemical recurrence, distant metastasis (DM), prostate cancer-specific mortality, and other-cause mortality. RESULTS: The median (IQR) age among the 10 266 male patients was 70 (65-74) years. Longer durations of ADT were associated with nonlinear improvement in relative benefits of DM, prostate cancer-specific mortality, and overall survival, with reduced estimated benefits beyond 9 to 12 months of ADT based on the end point. There was a near-linear increase in other-cause mortality associated with long-term ADT use (hazard ratio, 1.28; 95% CI, 1.09-1.50; P = .002 for 28 vs 0 months of ADT). The optimal ADT duration based on 10-year DM was 0, 6, 12 months, and undefined for patients with 1 intermediate-risk factor, 2 or more intermediate-risk factors, and National Comprehensive Cancer Network high-risk and very high-risk disease, respectively. CONCLUSIONS AND RELEVANCE: The results of this meta-analysis suggest that, for men with localized prostate cancer treated with definitive radiotherapy and ADT, there are relative and absolute benefits from increasing durations of ADT that help provide individualized risk estimates.
引用
- Zaorsky NG, Sun Y, Nabid A, et al. Optimal Duration of Androgen Deprivation Therapy With Definitive Radiotherapy for Localized Prostate Cancer: A Meta-Analysis. JAMA Oncol. 2026. PMID: 41264309. doi:10.1001/jamaoncol.2025.4800
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。